Latest News

Press Release – Oslo, Norway, 6 April 2021, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews at two upcoming Healthcare Conferences in April.

Oslo, Norway, 29 March 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 25 March 2021 regarding a share capital increase following the exercise of share options.

Oslo, Norway, 26 March 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 25 March 2021 regarding exercise of share options.

The price for option shares sold by primary insiders have been determined at a price of NOK 130.6672 per share.

Oslo, Norway, 26 March 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 25 March 2021 regarding initiation of a share buyback program.

Oslo, Norway, 25 March 2021: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 25 March 2021 exercised a total of 102,533 options distributed as follows:

Oslo, Norway, 25 March 2021: Photocure ASA ("Photocure" or the "Company") has decided to initiate a buyback of up to 72,500 of its own shares for a total maximum amount of NOK 10,875,000. The buyback program may be carried out in the period from this announcement and until 22 April 2021.

A recently published systematic review and network meta-analysis of randomized controlled trials investigated the impact of enhanced optical techniques at time of TURBT* with or without single immediate intravesical chemotherapy (SIIC) on recurrence rate of non-muscle-invasive bladder cancer (NMIBC).

Oslo, Norway, 3 March 2021: Photocure ASA (OSE:PHO) reports Hexvix^®/Cysview^® revenues of NOK 97.7 million in the fourth quarter of 2020 (Q4 2019: NOK 58.8). Product revenues increased 20% in FY2020 representing strong execution in an unprecedented year. Due to the ongoing pandemic, the Company suspends guidance for its 2023 revenue ambition in the range of NOK 1 billion. Photocure plans to re-issue financial guidance once the impact from Covid-19 is significantly diminished and physician practices and patient flow have normalized in both the U.S. and Europe.

Oslo, Norway, 24 February 2021: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2020 financial results on Wednesday 3 March 2021 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

A new study in Germany based on real life claims data compares costs of initial TURBT in bladder cancer treatment using standard white light- vs. blue light-TURBT* in 4500+ patients.

Agreement Expands Photocure’s Hexvix^®/Cysview^® Franchise Footprint to over 30 Countries

Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients,  announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix^® in Mainland China and Taiwan.
 

*Number of shares following registration of share issue is corrected

Oslo, Norway, 15 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 3 December 2020 regarding registration of a share capital increase following the exercise of share options.

PRESS RELEASE – Oslo, Norway, 7 December, 2020: Photocure ASA (OSE:PHO) today announced new data and analyses presented at the 21^st Annual Meeting of the Society of Urologic Oncology (SUO). Presentations discussed the use of Blue Light Cystoscopy (BLC™) with Cysview^®, in particular the positive impact on patient outcomes in the surveillance setting without a significant impact on the cost of care, as well as the benefits of identifying early recurrences in high-risk NMIBC patients undergoing BCG treatment.

Oslo, Norway, 3 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 December 2020 regarding a share capital increase following the exercise of share options.

Oslo, Norway, 1 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 November 2020 regarding exercise of share options.

Oslo, Norway, 30 November 2020: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 30 November 2020 exercised a total of 90,150 options distributed as follows:

Oslo, Norway, 11 November, 2020: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals has initiated the phase III clinical trial for APL-1702 (Cevira^®), triggering a USD 1.5 million milestone payment under the global licensing deal.

Oslo, Norway, 10 November 2020: Photocure ASA (OSE:PHO) today reported Hexvix^®/Cysview^® revenues of NOK 49.6 million in the third quarter of 2020 (Q3 2019: NOK 51.1), with the U.S. market continuing the Covid-19 rebound with a growth of 20%. Photocure has successfully launched the European Hexvix operations and reiterates the strong outlook and 2023 ambitions.